Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

API Manufacturing: SOP for Handling Discrepant IPC Observations – V 2.0

Posted on By

API Manufacturing: SOP for Handling Discrepant IPC Observations – V 2.0

Standard Operating Procedure for Handling Discrepant IPC Observations in API Manufacturing

Department API Manufacturing
SOP No. SOP/API/116/2025
Supersedes SOP/API/116/2022
Page No. Page 1 of 10
Issue Date 13/04/2025
Effective Date 15/04/2025
Review Date 13/04/2026

1. Purpose

To establish a procedure for managing discrepancies observed in IPC (In-Process Control) data during API manufacturing, including unusual, inconsistent, or unexpected results, ensuring timely identification, investigation, correction, and documentation as per cGMP.

2. Scope

This SOP applies to all IPC parameters monitored during the production of APIs and intermediates, where observed results deviate from expected trends or

show inconsistencies due to operator error, equipment fault, or sampling issues.

3. Responsibilities

  • Production Chemist: Immediately report any discrepant observation to QA and document the initial finding in the IPC sheet.
  • QC Analyst: Assist in confirmation and repeat testing (if justified), and provide analytical insight.
  • QA Officer: Initiate deviation process, perform investigation, and ensure resolution of discrepancy.
See also  API Manufacturing: SOP for Monitoring Warehouse Temperature and Humidity - V 2.0

4. Accountability

The QA Head is accountable for the review, classification, and closure of discrepant IPC observations. The Production Head is accountable for ensuring timely notification and execution of corrective actions.

5. Procedure

5.1 Identification of Discrepant Observation

  1. A discrepant observation is defined as:
    • Sudden variation in result from previous trend
    • Fluctuating readings within a short interval
    • Unusually high/low readings despite correct process settings
    • Observation not matching batch behavior (e.g., visual, pH, temperature)
  2. On identification, halt further processing of the affected stage until QA is notified and assessment is performed.

5.2 Immediate Actions

  1. Document the discrepancy in the IPC logbook with:
    • Date and time
    • Parameter and equipment used
    • Observation details
    • Operator signature
  2. Notify the QA team and shift supervisor immediately.
  3. Place equipment “On Hold” if malfunction is suspected.
See also  API Manufacturing: SOP for Use of Cooling Towers and Condensers in Recovery - V 2.0

5.3 Investigation and Classification

  1. QA will initiate deviation as per SOP/API/115/2025 and conduct a root cause analysis (RCA).
  2. Determine potential causes:
    • Sampling error
    • Instrument calibration or functionality error
    • Environmental influence
    • Operator error
  3. Classify the discrepancy as:
    • Minor (no impact on product quality)
    • Major (requires CAPA, may affect next stage)
    • Critical (impact on product quality or safety)

5.4 Retesting Criteria

  1. Retesting shall be permitted only if:
    • There is clear evidence of error in sampling or instrument use
    • QA has approved the justification for retesting
    • Retesting is documented in Deviation Form and IPC Sheet

5.5 Corrective Action

  1. Implement appropriate action based on investigation outcome, such as:
    • Retraining of staff
    • Repair or recalibration of equipment
    • Procedure revision
    • Process adjustment (if deviation is accepted with impact evaluation)
  2. Record action taken in Deviation Report and obtain QA approval for closure.

6. Abbreviations

  • IPC: In-Process Control
  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • QC: Quality Control
  • RCA: Root Cause Analysis
  • CAPA: Corrective and Preventive Action
See also  API Manufacturing: SOP for Reporting Deviations in IPC Parameters - V 2.0

7. Documents

  1. Discrepant IPC Observation Report (Annexure-1)
  2. Deviation Register
  3. IPC Logbook

8. References

  • ICH Q10 – Pharmaceutical Quality System
  • 21 CFR Part 211 – cGMP for Finished Pharmaceuticals
  • WHO TRS 986 – GMP Guidelines

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Discrepant IPC Observation Report

Date Batch No. Parameter Observed Value Expected Suspected Cause Action Taken QA Comments
13/04/2025 API-20250413 Temperature 42°C 30–35°C Equipment sensor drift Sensor Replaced Approved for closure

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial SOP Release Regulatory Requirement QA Head
13/04/2025 2.0 Added structured classification and retesting rules Audit Recommendation QA Head
API Manufacturing V 2.0 Tags:API batch record, API BMR, API calibration, API centrifuge, API cleaning, API crystallization, API deviation, API documentation, API drying, API equipment cleaning, API filtration, API GMP compliance, API granulation, API hold time, API impurities, API line clearance, API manufacturing, API process, API quality control, API reactor, API sampling, API solvent handling, API validation, API waste disposal, API yield

Post navigation

Previous Post: Biosimilars: SOP for Media Preparation and Sterilization – V 2.0
Next Post: Elixir Department: SOP for Preparation and Addition of Sugar Syrup – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version